jRCT2080221773未知3 期
Phase 3 clinical study of RM-003 in patients with homocystinuria
试验速览
- 阶段
- 3 期
- 入组人数
- 8
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Non-randomized, unblinded, uncontrolled, multicenter study
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •Homocystinuria, described as the following cases
- •cystathionine beta-synthase deficiency(CBS)
- •5,10-methylenetetrahydrofolate reductase deficiency
- •defects in cobalamin metabolism
排除标准
- 未提供
结局指标
主要结局
-
Plasma total homocysteine levels at the end of the treatment
次要结局
- Plasma total homocysteine levels(each visit of the treatment)
- Plasma homocystine levels(end of the treatment)
研究者
相似试验
未知
3 期
Phase 3 clinical study of RM-003 in patients with homocystinuriaHomocystinuria, described as the following casescystathionine beta-synthase deficiency(CBS), 5,10-methylenetetrahydrofolate reductase deficiency, defects in cobalamin metabolismJPRN-jRCT2080221773ReqMed Company, Ltd.8
未知
3 期
Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA)sJIAJPRN-jRCT2080220017Chugai Pharmaceutical Co., Ltd.
进行中（未招募）
不适用
A phase III clinical study in patients with active rheumatoid arthritis who show an inadequate response or intolerance to previous or current treatmentRheumatoid ArthritisjRCT2011220026Zenyaku Kogyo, Co., Ltd.113
进行中（未招募）
1 期
Reversal of dabigatran anticoagulant effect with idarucizumabHemorrhageMedDRA version: 18.1Level: LLTClassification code 10019524Term: HemorrhageSystem Organ Class: 100000004866EUCTR2013-004813-41-FIBoehringer Ingelheim Finland Ky250
进行中（未招募）
1 期
Reversal of dabigatran anticoagulant effect with idarucizumabHemorrhageMedDRA version: 18.1Level: LLTClassification code 10019524Term: HemorrhageSystem Organ Class: 100000004866EUCTR2013-004813-41-IEBoehringer Ingelheim Limited500